<DOC>
	<DOCNO>NCT02256306</DOCNO>
	<brief_summary>The PLasma Alzheimer SymptoM Amelioration ( PLASMA ) Study : Intravenously-Administered Plasma From Young Donors Treatment Mild-To-Moderate Alzheimer 's Disease</brief_summary>
	<brief_title>The PLasma Alzheimer SymptoM Amelioration ( PLASMA ) Study</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable Alzheimer 's disease ( NIAAA criterion ) MiniMental State Examination ( MMSE ) score 1224 Availability study partner know patient well willing accompany subject trial visit , participate questionnaire complete daily journal assessment Pregnancy unwilling use adequate birth control method duration 6 month beyond study participation Positive Hepatitis B , Hepatitis C HIV screen Any condition situation investigator believe may interfere safety subject intent conduct study Related medical history : Stroke Anaphylaxis Prior adverse reaction human blood product Any history blood coagulation disorder hypercoagulability Congestive heart failure Uncontrolled hypertension Renal failure Prior intolerance intravenous fluid Recent history uncontrolled atrial fibrillation IgA deficiency ( history ) Related medication treatment : Any concurrent use anticoagulant therapy . Antiplatelet drug ( e.g. , aspirin clopidogrel ) acceptable Initiation change dosage cholinesterase inhibitor memantine trial . A participant already cholinesterase inhibitor memantine must stable dose least one month prior Screening Concurrent participation another treatment trial Alzheimer 's disease . If prior participation , last dose investigational agent must least 6 month prior Screening Treatment human blood product , include intravenous immunoglobulin , 6 month prior Screening trial Concurrent daily treatment benzodiazepine , typical atypical antipsychotic , longacting opioids , medication , investigator 's opinion , interfere cognition . Intermittent treatment shortacting benzodiazepine atypical antipsychotic may permit , provide dose administer within 72 hour precede cognitive assessment Related magnetic resonance imaging : Claustrophobia Any metallic surgical implant , like pacemaker clip incompatible 3T MRI . Certain metallic implant like joint replacement may permit , provide specific manufacturer specification available device know safe 3T MRI .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>